

REMARKS

Applicant, through the undersigned, wishes to thank Examiner Whiteman and Supervisory Examiner Burke for the courtesy and assistance extended on behalf of Applicant during a telephone interview conducted on March 31, 2005.

In the Final Action dated January 14, 2005, claims 16-30 are pending and under consideration. The Examiner has objected to the reissue declaration because the declaration does not state that all errors being corrected in the instant reissue declaration arose without deceptive intention. Claims 16-30 are objected to under 35 U.S.C. §251 as being based on a defective reissue declaration. The specification is objected to for allegedly failing to comply with the Sequence Rules. Claims 16-30 are objected to because of certain informalities.

This Response addresses each of the Examiner's objections and rejections. Accordingly, it is respectfully submitted that the present application is in condition for allowance. Favorable consideration of all pending claims is therefore respectfully requested.

Regarding the objection to the declaration, Applicant respectfully submits herewith a supplemental reissue declaration, which now states that all errors being corrected in the instant reissue declaration arose without deceptive intention on the part of Applicant. As such, withdrawal of the objection to the declaration and the rejection of claims 16-30 based on a defective declaration is therefore respectfully requested.

Regarding the objection to the specification, the Examiner states that the sequence that appears in Figure 2A is not listed in the Sequence Listing.

Applicant respectfully submits that the sequence depicted in Figure 2A is part of SEQ ID NO: 2. In fact, Figure 2A and Figure 2B, together, depict one single, continuous, double-stranded nucleic acid sequence. To clarify, Applicant has amended the drawing description to

recite that "Figure 2A and Figure 2B, joined at the match line", depict the double-stranded nucleotide sequence of SEQ ID NO: 2. As such, the objection to the specification is overcome. Withdrawal of the objection is respectfully requested.


Regarding the objection to the format of claims 16-30, the Examiner states that for each new claim added to the reissue application by the amendment being submitted, the entire text of the added claim must be completely underlined.

Accordingly, Applicant has represented the amendments to the claims, relative to the patent claims, in the format required under 37 C.F.R. §1.173. Furthermore, Applicant has presented in accordance with the provisions of 37 C.F.R. §1.173(c), on a separate page, the status of all patent claims and all added claims, as well as support for the changes made relative to the patent claims. Thus, the objection to the format of the claims is overcome. Withdrawal of the objection is therefore respectfully requested. Applicant is also providing a courtesy copy of the marked up version of the present claims, showing the changes made relative to the claims presented in the Preliminary Amendment dated July 16, 2003.

During the interview on March 31, 2005, the Examiner has also requested that Applicant explain the term, "a non-biologically functionally protein", as recited in claim 20. Applicant respectfully directs the Examiner's attention to col. 7, lines 15-19 of the specification, where non-biologically functionally proteins are described. Applicant respectfully submits that in light of the specification, the term is clear to those skilled in the art.

In view of the foregoing amendments and remarks, it is firmly believed that the subject application is in condition for allowance, which action is earnestly solicited.

Respectfully submitted,



Kenneth L. Cage
Registration No. 26,151

McDermott, Will & Emery
600 13th Street, N.W.
Washington, D.C. 20005-3096
Tel: (202) 756-8363

Date: June 13, 2005

Enc.: Supplemental Declaration; Marked-up Copy of Claims.

MARKED-UP COPY – COURTESY ONLY. DO NOT ENTER.

16. An expression vector comprising two inverted terminal repeats of adeno-associated virus 2 and at least one cassette comprising a promoter capable of effecting cell-specific expression, wherein each of said inverted terminal repeats is SEQ ID NO: 1 or a fragment of SEQ ID NO: 1 that comprises nucleotides 1 to 125 of SEQ ID NO: 1, wherein said promoter is operably linked to a heterologous gene, and wherein said cassette resides between said inverted terminal repeats.

17. The vector of claim 16 wherein each of said inverted terminal repeats ~~comprises the nucleotides of~~ is SEQ ID NO:1.

18. The vector of claim 16 wherein each of said inverted terminal repeats is a fragment of SEQ ID NO: 1 that comprises nucleotides 1 to 125 of SEQ ID NO:1.

19. The vector of claim 16 wherein said heterologous gene encodes a biologically functional protein.


20. The vector of claim 16 wherein said heterologous gene encodes a non-biologically functional protein.

21. The vector of claim 16 wherein said heterologous gene encodes an antisense RNA.

22. The vector of claim 16 wherein said heterologous gene is selected from the group consisting of a gene encoding α -globin, β -globin, γ -globin, granulocyte macrophage-colony stimulating factor (GM-CSF), tumor necrosis factor (TNF), any one of interleukins 1-11, neomycin resistance, luciferase, adenine phosphoribosyl transferase (APRT), retinoblastoma, insulin, mast cell growth factor, p53, and adenosine deaminase.

23. The vector of claim 16 wherein said heterologous gene encodes P-glycoprotein.

24. The vector of claim 21 wherein said antisense RNA is complementary to a segment of the DNA or RNA encoding α -globin.
25. The vector of claim 16 wherein said vector is AAV-B19-mdr.
26. A host cell transfected by the vector of any one of claims 16-25.
27. The host cell of claim 26 wherein said cell is a hematopoietic stem or hematopoietic progenitor cell.
28. A virion comprising the vector of any one of claims 16-24.
29. A host cell infected by the virion of claim 28.
30. The host cell of claim 29 wherein said cell is a hematopoietic stem or progenitor cell.



PATENTS

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Arun Srivastava

Art Unit: 1635

Application No.: 10/620,039

Examiner: Whiteman, Brian A.

Filed: July 16, 2003

Docket: 44141-034RI (8361z)

For: VECTOR FOR GENE THERAPY

Confirmation No.: 8203

Commissioner for Patents
United States Patent and Trademark Office
Alexandria, Virginia 22313-1450

**DECLARATION IN SUPPORT OF
REISSUE UNDER 37 C.F.R. §§ 1.175 and 1.63**

Sir:

I, Arun Srivastava, declare and state as follows:

1. I am a U.S. citizen and currently reside at 3823 SW 92nd Drive, Gainesville, FL 32608.
2. I believe that I am the original, first and sole inventor of the subject matter which is described and claimed in U.S. Patent No. 6,261,834 ("834 patent"), granted on July 17, 2001, and for which I solicit a reissue patent.
3. The '834 patent is assigned to Research Corporation Technologies, Inc., Tucson, AZ. As in the '834 patent, the instant reissue application claims priority from International Application PCT/US92/09769, filed on November 6, 1992.

5. I believe that the '834 patent is partly inoperative or invalid by reason of claiming less than there was a right to claim in one aspect and claiming more than there was a right to claim in another aspect.

6. Independent claim 1 is directed to an expression vector. The structural features of the expression vector are set forth in claim 1 as comprising "two inverted terminal repeats of adeno-associated virus 2 and at least one cassette comprising a promoter capable of effecting cell-specific expression wherein said promoter is operably linked to a heterologous gene, and wherein said cassette resides between said inverted terminal repeats." The expression vector is characterized in the preamble as "for site-specific integration and cell-specific gene expression".

7. I believe that the invention of claim 1 of the '834 patent is properly implemented without the preamble expression "for site-specific integration and cell-specific gene expression." A principal feature provided by the '834 patent resides in the recognition that cell-specific expression of a heterologous gene can be achieved by placing such gene under control of a cell-specific promoter and between two ITR sequences of AAV. The AAV ITR sequences achieve stable integration into the host genome without causing substantial toxicity to the host cells, in contrast to the random integration of retroviral vectors. The critical structural elements of the expression vector, i.e., a cell-specific promoter, a heterologous gene and two AAV ITR repeats, are already set forth in claim 1. The preamble "for site-specific integration and cell-specific gene expression" merely describes certain mechanistic features of the recombinant AAV vector and is not necessary for the purpose of defining the expression vector. It is unclear as to whether such mechanistic features in the preamble should be read as a limitation of the expression vector of claim 1. To the extent that such mechanistic features

will be read as a limitation of the expression vector of claim 1, I believe that claim 1 is too narrow and the patent claimed less than there was a right to claim in the patent.

8. This error of claiming less than there was a right to claim in the patent to the extent that the preamble expression is read as a limitation of the claimed expression vector, arose without any deceptive intention on my part.

9. To correct this error and to claim what the patentee had a right to claim, claims 1-15 are canceled and new claims 16-30 are added in the instant reissue application. Claim 16, directed to an expression vector, does not contain the expression "for site-specific integration and cell-specific gene expression." Claims 17-30, which depend from claim 16, are written in the same manner as dependent claims 2-15 of the '834 patent.

10. During prosecution of the instant reissue application, it has come to my attention that U. S. Patent 5,436,146 has issued to Shenk et al. ("Shenk"). Shenk teaches a recombinant AAV vector containing terminal AAV sequences and a foreign DNA sequence operably linked to a promoter. Shenk discloses the use of 191 bp segments from the termini of psub201, a vector which contains AAV-2 DNA. Further, Shenk discloses, in the form of a laundry list, tissue specific promoters that can be employed in the recombinant AAV vector, although Shenk does not provide any showing of tissue specific expression of a heterologous gene from the recombinant AAV vector.

11. To the extent that the expression vector of the '834 patent is considered to be anticipated by Shenk, I believe that the '834 patent is partly inoperative or invalid by reason of claiming more than there was a right to claim.

12. This error of claiming more than there was a right to claim in the patent to the extent that the expression vector is considered to be anticipated by Shenk, arose without any deceptive intention on my part.

13. To correct this error and to claim what the patentee had a right to claim, claim 16 is written to recite "wherein each of said inverted terminal repeats is SEQ ID NO: 1 or a fragment of SEQ ID NO: 1 that comprises nucleotides 1 to 125 of SEQ ID NO: 1." Support for such recitation is found in the specification, e.g., on col. 9, lines 41-45. Shenk does not teach a recombinant AAV-2 vector, as characterized in claims 16-30.

14. All errors in the '834 patent, which I seek to correct by the instant reissue application, arose without any deceptive intention on my part.

15. I acknowledge the duty to disclose information which is material to the examination of this application in accordance with 37 C.F.R. § 1.56.

16. I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Dated: May 4, 2005

Arun Srivastava
Arun Srivastava